WALTHAM, Mass. and VIENNA, Austria, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $10.00 per share. The gross proceeds to Arsanis from the offering are expected to be $40.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Arsanis has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock from Arsanis at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares are being offered by Arsanis. Arsanis’ shares are scheduled to begin trading on The NASDAQ Global Market on November 16, 2017 under the ticker symbol “ASNS.”
The offering is expected to close on November 20, 2017, subject to customary closing conditions.
In addition, a fund affiliated with New Enterprise Associates has agreed to purchase $20.0 million of Arsanis' common stock in a separate private placement concurrent with the completion of Arsanis' initial public offering at a price per share equal to the initial public offering price. The closing of the initial public offering is not conditioned upon the closing of the concurrent private placement.
Citigroup, Cowen and Company and Piper Jaffray & Co. are acting as joint book-running managers for the public offering and as placement agents for the concurrent private placement.
A registration statement relating to the securities to be offered and sold in the initial public offering has been filed with, and was declared effective by, the Securities and Exchange Commission on November 15, 2017. Copies of the registration statement can be accessed by visiting the Securities and Exchange Commission website at www.sec.gov.
This offering is being made only by means of a prospectus. A preliminary prospectus describing the terms of the offering has been filed with the Securities and Exchange Commission and forms a part of the effective registration statement. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission, and may be obtained, when available, from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (631) 274-2806; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build and advance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets. The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in a Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.
Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
This press release includes certain disclosures which contain “forward-looking statements,” including, without limitation, statements regarding the anticipated timing of completion of the offerings of Arsanis’ common stock. You can identify forward-looking statements because they contain words such as “believes” and “expects.” Forward-looking statements are based on Arsanis’ current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Arsanis’ filings with the SEC, including its registration statement on Form S-1, as amended from time to time, under the caption “Risk Factors.”
Ten Bridge Communications
Chief Operating and Chief Financial Officer
Source: Arsanis, Inc.